Navigation Links
Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
Date:7/17/2012

EAST BRUNSWICK, N.J., July 17, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's second quarter 2012 financial results will be released prior to the market open on Wednesday, August 8, 2012.  Savient's executive management will host a conference call beginning at 9:00 a.m. Eastern Time on August 8, 2012 to discuss these results and to answer questions.

To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151 (International). The conference ID number is 99954484.  The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.
A telephone replay will be available for fourteen days by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 99954484.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) C
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
2. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development
5. Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift from Traditional Mass-Media Platforms towards Personalization via Online and Social Media
6. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
7. 81,200 Square Foot Lease Extension In San Diego Through 2018 Signed By Vertex Pharmaceuticals And BioMed Realty
8. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
9. Ampio Pharmaceuticals Announces Exercise of Over-Allotment Option
10. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
11. ResearchMoz.US: Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift From Traditional Mass-Media Platforms Towards Personalization via Online and Social Media- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013 China Biologic Products, Inc. (Nasdaq: ... integrated plasma-based biopharmaceutical company in China ... from a public announcement issued by Shanghai RAAS Blood ... on Shenzhen Stock Exchange, that on May 21, 2013, ... Chan"), one of the shareholders of the Company, and ...
(Date:5/24/2013)... The potential of the pulmonary ... therapeutic agents has been receiving undeniable attention with the ... promise. The crucial formulation considerations for orally inhaled products ... major role in the efficiency of pulmonary delivery, and ... new formulation techniques and devices in recent years. ...
(Date:5/23/2013)... SAN DIEGO y PARÍS, 24 de ... VOLC ), un destacado desarrollador y fabricante ... para mejorar la diagnosis y tratamiento de la ... resultados preliminares del ensayo ADVISE ( Ad enosine ... tenosis E valuation) II durante la sesión ...
Breaking Medicine Technology:China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
(Date:5/25/2013)... Texas (PRWEB) May 25, 2013 ... stressful than finals week. Increasingly, they are turning ... stay awake and study. For more on this, ... a drug treatment facility, warns that students who ... finals” are at risk for developing a physical ...
(Date:5/25/2013)... Ayurveda is the traditional medicine ... wisdom of life". While a medical science, its scope enters ... consciousness. Its fundamental philosophy is that disease is the end ... believes that in order to re-establish optimal health, we must ... adopt a life style which brings us back into harmony. ...
(Date:5/25/2013)... Flagstaff, Arizona (PRWEB) May 25, 2013 The ... Rehabilitation Center, their parents, and the B2B staff all came ... While everyone enjoyed an array of Indian Cuisine, the residents ... the company, for helping them on their road to recovery, ... started the Drug and Alcohol center in 2010 after realizing ...
(Date:5/25/2013)... http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html , Resource4thePeople is ... of a jury's award of $6.5 million in damages ... the country over allegations that the diabetes drug Actos ... The judge in the case ruled that the man's ... was caused by the medication.** , Bloomberg News in ...
(Date:5/25/2013)... 25, 2013 AdvantaClean of Pikes Peak ... services for a healthy home and business in Colorado ... damage , mold inspections, mold testing, mold removal ... and coil cleaning. , With over 120 offices nationwide, ... industry offering a full suite of services for commercial, ...
Breaking Medicine News(10 mins):Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 3Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 4Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 2Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 3Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 4
... Grants New Indication for Bothersome Vaginal Symptom Associated,With ... estrogens) Vaginal Cream 0.5 g has been approved ... a new indication and a new less,frequent twice-weekly ... (painful sexual intercourse) announced Wyeth,Pharmaceuticals, a division of ...
... from patients with lung cancer and examining them under ... utilized to better tailor the chemotherapy treatments to improve ... according to a study presented at the 2008 Chicago ... IASLC and the University of Chicago., Cancer researchers have ...
... tumors of African-American non-small cell lung cancer patients are ... of the epidermal growth factor receptor (EGFR) gene and ... a study presented at the 2008 Chicago Multidisciplinary Symposium ... the University of Chicago., These genetic factors have been ...
... are one milliard of a metre in size are ... materials. There are also significant amounts of nanoparticles in ... their health effects, because only a very small portion ... and safety risks. Nanoparticles have even been dubbed the ...
... http://www.HealthCentral.com ) the leading collection of condition-specific,consumer ... a,broad initiative to sell advertising for any ... partners on a,non-exclusive basis and not require ... party rankings., "We are changing the ...
... those shoppers who,wake up at 4am on Black Friday? Not ... is important not to disturb your circadian rhythm and to ... body,operates better on a good night,s sleep which is why ... the day after Thanksgiving.", SSA retailers nationwide have an ...
Cached Medicine News:Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 2Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 3Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 4Health News:Research demonstrates differing genetic makeup of lung cancer in African-American patients 2Health News:Nanoparticles trigger cell death? 2Health News:HealthCentral Announces New Condition-Specific Ad Service to Offer Marketers the Highest Qualified Audiences 2Health News:Don't Disturb Your Circadian Rhythm This Black Friday 'Sleep In, Nap Later,' says Specialty Sleep Association 2
The K-ASSAY Fibrinogen Control is an assayed quality control material intended for use in monitoring the accuracy and precision of the quantitative determination of fibrinogen....
The K-ASSAY Anti-Streptolysin O Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assay for quantifyi...
Eppendorf expands its line of benchtop microcentrifuges with the 5418. This easy-to-use microcentrifuge features a certified aerosol-tight rotor and a unique, contoured rotor bowl design to reduce no...
... Directigen EZ Flu A+B test is a ... qualitative detection of influenza A and B ... swabs of symptomatic patients. The Directigen EZ ... such that influenza A viral antigens can ...
Medicine Products: